Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 296 participants.
Also called NCT01272193
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 296 participants
- Sponsor
- Registry
-
NCT01272193
-
- Other papers using this trial's data
- Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01272193. Randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2015-11-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
- Acronym
- BOOST™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01272193- Content hash
f5e470958afeb9a02b96ec9af22cc9c11ba43e159040e3ffff5e977ef3a82814